168 related articles for article (PubMed ID: 17440014)
21. Multiple endocrine neoplasia, type 2b.
Carney JA; Sizemore GW; Hayles AB
Pathobiol Annu; 1978; 8():105-53. PubMed ID: 364372
[TBL] [Abstract][Full Text] [Related]
22. Oncocytic lesions of the neuroendocrine system.
Baloch ZW; LiVolsi VA
Semin Diagn Pathol; 1999 May; 16(2):190-9. PubMed ID: 10452583
[TBL] [Abstract][Full Text] [Related]
23. Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression.
Rindi G; Grant SG; Yiangou Y; Ghatei MA; Bloom SR; Bautch VL; Solcia E; Polak JM
Am J Pathol; 1990 Jun; 136(6):1349-63. PubMed ID: 2162628
[TBL] [Abstract][Full Text] [Related]
24. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.
La Rosa S; Uccella S; Finzi G; Albarello L; Sessa F; Capella C
Hum Pathol; 2003 Jan; 34(1):18-27. PubMed ID: 12605362
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromogranin and endocrine granule constituent in neuroendocrine tumours.
Vyberg M; Horn T; Francis D; Askaa J
Acta Histochem Suppl; 1990; 38():179-81. PubMed ID: 1964227
[TBL] [Abstract][Full Text] [Related]
26. Synaptic vesicle protein 2, A new neuroendocrine cell marker.
Portela-Gomes GM; Lukinius A; Grimelius L
Am J Pathol; 2000 Oct; 157(4):1299-309. PubMed ID: 11021834
[TBL] [Abstract][Full Text] [Related]
27. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors.
Komminoth P; Roth J; Schröder S; Saremaslani P; Heitz PU
Lab Invest; 1995 Apr; 72(4):424-31. PubMed ID: 7723281
[TBL] [Abstract][Full Text] [Related]
28. [A case of multiple endocrine neoplasia, type 1, with parathyroid adenoma, multinodular adrenal cortical hyperplasia, islet cell tumor and hyperplasia of thyroid with concomitant hypersecretion of gastrin and total glucagon-like immunoreactivity].
Shigematsu S; Shimoyama N; Sato Y; Horita M; Oribe Y; Ono J; Takaki R; Ishimatsu T; Kodama M; Iwashita K
Nihon Naika Gakkai Zasshi; 1989 Mar; 78(3):357-62. PubMed ID: 2567324
[No Abstract] [Full Text] [Related]
29. [C cell hyperplasia and C cell carcinoma within the framework of multiple endocrine neoplasms].
John HD
Pathologe; 1983 Mar; 4(2):71-81. PubMed ID: 6134278
[No Abstract] [Full Text] [Related]
30. Islet amyloid polypeptide-like immunoreactivity in human tissue and endocrine tumors.
Bretherton-Watt D; Ghatei MA; Bloom SE; Williams S; Bloom SR
J Clin Endocrinol Metab; 1993 Apr; 76(4):1072-4. PubMed ID: 8473384
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands.
Takiyyuddin MA; Cervenka JH; Pandian MR; Stuenkel CA; Neumann HP; O'Connor DT
J Clin Endocrinol Metab; 1990 Aug; 71(2):360-9. PubMed ID: 2116438
[TBL] [Abstract][Full Text] [Related]
32. Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors.
Rindi G; Solcia E
Gastroenterol Clin North Am; 2007 Dec; 36(4):851-65, vi. PubMed ID: 17996794
[TBL] [Abstract][Full Text] [Related]
33. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
34. Polyoma-induced neoplasms of the mouse adrenal medulla. Characterization of the tumors and establishment of cell lines.
Tischler AS; Freund R; Carroll J; Cahill AL; Perlman RL; Alroy J; Riseberg JC
Lab Invest; 1993 May; 68(5):541-9. PubMed ID: 8098784
[TBL] [Abstract][Full Text] [Related]
35. Genetics of pheochromocytomas and paragangliomas.
Opocher G; Schiavi F
Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163
[TBL] [Abstract][Full Text] [Related]
36. Molecular abnormalities in tumors associated with multiple endocrine neoplasia type 2.
Nelkin BD; Ball DW; Baylin SB
Endocrinol Metab Clin North Am; 1994 Mar; 23(1):187-213. PubMed ID: 7913025
[TBL] [Abstract][Full Text] [Related]
37. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
Ye L; Santarpia L; Gagel RF
Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
[TBL] [Abstract][Full Text] [Related]
38. Immunoreactivity of N-terminal fragment of gastrin-releasing peptide as histochemical marker for pancreatobiliary duct-type cells.
Tsutsumi Y; Nagura H; Watanabe K; Yanaihara N
Lab Invest; 1984 Jan; 50(1):94-100. PubMed ID: 6363818
[TBL] [Abstract][Full Text] [Related]
39. Endocrine neoplasia in New World primates.
Dias JL; Montali RJ; Strandberg JD; Johnson LK; Wolff MJ
J Med Primatol; 1996 Jan; 25(1):34-41. PubMed ID: 8740950
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and predictive factors in endocrine tumours.
Stephenson TJ
Histopathology; 2006 May; 48(6):629-43. PubMed ID: 16681678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
